Loading...
•
Mar 31, 2021
Eagle Q1 2021 Earnings Report
Reported a net loss of $0.03 per basic and diluted share, with adjusted non-GAAP net income of $0.24 per basic and diluted share.
Key Takeaways
Eagle Pharmaceuticals reported Q1 2021 results with total revenue of $41.2 million compared to $46.0 million in Q1 2020. The company had a net loss of $0.4 million, or $0.03 per share, and an adjusted non-GAAP net income of $3.2 million, or $0.24 per share.
Q1 2021 total revenue was $41.2 million, compared to $46.0 million in Q1 2020.
Q1 2021 net loss was $0.03 per basic and diluted share.
Adjusted non-GAAP net income for Q1 2021 was $0.24 per basic and diluted share.
The company anticipates vasopressin approval and launch this year.
Eagle
Eagle
Forward Guidance
Eagle Pharmaceuticals anticipates vasopressin approval and launch this year and expects approximately $20-$25 million from combined royalty and milestone revenue in 2022 for TREAKISYM.
Positive Outlook
- Anticipate vasopressin approval and launch this year.
- Completed last required study for vasopressin.
- Expect to respond to vasopressin CRL in full by mid-year.
- Expects approximately $20-$25 million from combined royalty and milestone revenue in 2022 for TREAKISYM (bendamustine) Ready-to-Dilute (“RTD”) and Rapid Infusion (“RI”) formulations
- Outstanding and large opportunity with TREAKISYM in Japan representing another extension of our bendamustine franchise.